Clene Prices $4M Registered Direct Offering at $3.28; Insiders Commit $2.1M
CLNN sits 26% above its 52-week low of $3.25.
Summary
Clene priced a $4.0 million registered direct offering at $3.28 per share, with insiders taking about $2.1 million. Proceeds fund the CNM-Au8 NDA effort amid a going-concern warning.
Key Events · Financing and Capital Events · CLNN
-
$4M Registered Direct Offering Priced
Clene is selling 1,219,513 shares at $3.28 per share, raising approximately $4.0 million before insignificant expenses. No placement agent or underwriter is involved.
-
Insiders Commit $2.1M
Certain directors and officers agreed to purchase approximately $2.1 million of the offering at the same $3.28 price, which is equal to or greater than the consolidated closing bid price immediately before the Securities Purchase Agreement.
-
Dilution of $4.77 Per Share
New investors face immediate dilution of $4.77 per share — the difference between the $3.28 offering price and the pro forma as adjusted net tangible book value deficit of ($1.49) per share as of June 30, 2026.
-
Proceeds Fund CNM-Au8 NDA Effort
Net proceeds will support regulatory dialogue, preparation of regulatory filings, and the planned NDA for CNM-Au8, including expanded access protocols and potential commercialization efforts.
Analysis · CLNN · Life Sciences
Clene is raising $4.0 million by selling 1,219,513 shares at $3.28 each directly to existing stockholders, with directors and officers committing roughly $2.1 million of the total. The company has a going-concern warning and only $9.7 million in cash as of June 30, 2026, so this capital extends the runway for its planned NDA submission for CNM-Au8 in early Q4 2026. Insider participation at the same price as the last reported sale price is a modest positive, but the offering is dilutive — new investors face immediate book-value dilution of $4.77 per share.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 29.6% of the 1725 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLNN was trading at $4.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.6M. The 52-week trading range was $3.25 to $13.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.